No Data
No Data
Express News | OKYO Pharma Plans To Advance OK-101 Into Phase 2 Clinical Trial Of Neuropathic Corneal Pain Which Is Expected To Begin In Q3 2024
Why ConAgra Brands Shares Are Trading Lower? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Shares of Conagra Brands, Inc. (NYSE:CAG) fell during Thursday's session after the company reported worse-than-expected fourth-quarter sales results and issued FY25 adjusted EPS guidance below
Express News | OKYO Pharma Shares Are Trading Higher After the Company Announced Plan to Advance OK-101 Into a Phase 2 Clinical Trial of Neuropathic Corneal Pain
OKYO Pharma Advances OK-101 Into Phase 2 Trials
OKYO Pharma to Initiate Neuropathic Corneal Pain Trial for OK-101
Phase 2 randomized, placebo-controlled trial in neuropathic corneal pain (NCP) patients planned to begin in Q3, 2024OK-101 is believed to be the first IND clearance granted by FDA for a drug to begin clinical studies
Express News | HC Wainwright & Co. Reiterates Buy on OKYO Pharma, Maintains $7 Price Target
No Data